-
Je něco špatně v tomto záznamu ?
Granzyme B-induced apoptosis in cancer cells and its regulation (review)
I. Rousalova, E. Krepela
Jazyk angličtina Země Řecko
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NS9715
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Zdroj
NLK
Free Medical Journals
od 2006 do Před 1 rokem
PubMed
21042704
DOI
10.3892/ijo_00000788
Knihovny.cz E-zdroje
- MeSH
- aktivace enzymů MeSH
- apoptóza genetika MeSH
- biologické modely MeSH
- granzymy genetika metabolismus fyziologie MeSH
- lidé MeSH
- nádory enzymologie genetika metabolismus MeSH
- regulace genové exprese enzymů MeSH
- regulace genové exprese u nádorů MeSH
- tkáňová distribuce MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
The granzyme B-induced cell death has been traditionally viewed as a primary mechanism that is used by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to eliminate harmful target cells including allogeneic, virally infected and tumour cells. Granzyme B (GrB) is the most abundant serine protease which is stored in secretory granules of CTLs and NK cells. After recognition of the target cell, the engaged CTLs and NK cells vectorially secrete GrB along with other granule proteins including perforin into the immunological synapse. From this submicroscopic intercellular cleft GrB translocates into the cytoplasm of the target cell. Although several models have been proposed to explain the GrB delivery mechanism, conclusive understanding of this process remains still elusive. Once in the cytoplasm, GrB cleaves and activates, or inactivates, multiple protein substrates, resulting eventually into apoptotic demise of the target cell. This review is focused on the gene structure and expression of GrB, its biosynthesis and activation, delivery mechanisms into the target cell cytoplasm, direct proteolytic involvement in activation of several pro-apoptotic pathways, and on regulation of its activity in cancer cells. Moreover, emphasis is given to the GrB-mediated anticancer effects and future clinical applications of the GrB-based and tumour-targeted recombinant fusion constructs.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12026686
- 003
- CZ-PrNML
- 005
- 20160307111409.0
- 007
- ta
- 008
- 120816s2010 gr f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.3892/ijo_00000788 $2 doi
- 035 __
- $a (PubMed)21042704
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Roušalová, Ilona $7 xx0165190 $u Laboratories of Molecular and Cell Biology, Department of Pneumology and Thoracic Surgery, University Hospital Bulovka, 180 81 Prague 8, Czech Republic
- 245 10
- $a Granzyme B-induced apoptosis in cancer cells and its regulation (review) / $c I. Rousalova, E. Krepela
- 520 9_
- $a The granzyme B-induced cell death has been traditionally viewed as a primary mechanism that is used by cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells to eliminate harmful target cells including allogeneic, virally infected and tumour cells. Granzyme B (GrB) is the most abundant serine protease which is stored in secretory granules of CTLs and NK cells. After recognition of the target cell, the engaged CTLs and NK cells vectorially secrete GrB along with other granule proteins including perforin into the immunological synapse. From this submicroscopic intercellular cleft GrB translocates into the cytoplasm of the target cell. Although several models have been proposed to explain the GrB delivery mechanism, conclusive understanding of this process remains still elusive. Once in the cytoplasm, GrB cleaves and activates, or inactivates, multiple protein substrates, resulting eventually into apoptotic demise of the target cell. This review is focused on the gene structure and expression of GrB, its biosynthesis and activation, delivery mechanisms into the target cell cytoplasm, direct proteolytic involvement in activation of several pro-apoptotic pathways, and on regulation of its activity in cancer cells. Moreover, emphasis is given to the GrB-mediated anticancer effects and future clinical applications of the GrB-based and tumour-targeted recombinant fusion constructs.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a apoptóza $x genetika $7 D017209
- 650 _2
- $a aktivace enzymů $7 D004789
- 650 _2
- $a regulace genové exprese enzymů $7 D015971
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 _2
- $a granzymy $x genetika $x metabolismus $x fyziologie $7 D053804
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a biologické modely $7 D008954
- 650 _2
- $a nádory $x enzymologie $x genetika $x metabolismus $7 D009369
- 650 _2
- $a tkáňová distribuce $7 D014018
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Křepela, Evžen $7 xx0083612 $u Laboratories of Molecular and Cell Biology, University Hospital Bulovka, Prague, Czech Republic. krepelae@fnb.cz
- 773 0_
- $w MED00002350 $t International journal of oncology $x 1791-2423 $g Roč. 37, č. 6 (2010), s. 1361-1378
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21042704 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20160307111425 $b ABA008
- 999 __
- $a ok $b bmc $g 948728 $s 784032
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 37 $c 6 $d 1361-1378 $i 1791-2423 $m International journal of oncology $n Int J Oncol $x MED00002350
- GRA __
- $a NS9715 $p MZ0
- LZP __
- $b NLK122 $a Pubmed-20120816/11/01